|
pubmed:abstractText |
Previous human clinical trials of insulin-like growth factor type I (IGF-1) in amyotrophic lateral sclerosis (ALS) have been inconsistent. This phase III, randomized, double-blind, placebo-controlled study was undertaken to address whether IGF-1 benefited patients with ALS.
|
|
pubmed:affiliation |
Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA. sorenson.eric@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
